| Biomarker ID | 998 |
| PMID | 23046102 |
| Year | 2012 |
| Biomarker | AR |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 28 |
| Effect on Pathways | Pathways include: Prostate cancer, Androgen receptor signaling, proteolysis, and transcription regulation, SMAD2/3 nuclear pathway, Oocyte meiosis, SIDS susceptibility pathways |
| Experiment | Relpase Vs No Relapse |
| Type of Biomarker | Prognostic |
| Cohort | Study included 51 patients with distant relapse tumours, and 77 with no tumour relapse were included in the study. |
| Senstivity | 90% |
| Specificity | 75% |
| AUC | NA |
| Accuracy | 81% |
| Level Of Significance | p=0.001 |
| Method Used | real-time reverse-transcriptase PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |